Market capitalization | $1.60m |
Enterprise Value | $7.85m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-29.04m |
Free Cash Flow (TTM) Free Cash Flow | $-15.57m |
Cash position | $140.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Panbela Therapeutics Inc:
1 Analyst has issued a forecast Panbela Therapeutics Inc:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -29 -29 |
22%
22%
|
EBIT (Operating Income) EBIT | -29 -29 |
22%
22%
|
Net Profit | -28 -28 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The company was founded by Michael Cullen and Thomas Neenan on September 21, 2011 and is headquartered in Waconia, MN.
Head office | United States |
CEO | Jennifer Simpson |
Employees | 8 |
Founded | 2011 |
Website | www.panbela.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.